|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
US5352770A
(en)
|
1990-04-20 |
1994-10-04 |
Hisayuki Matsuo |
Porcine derived novel physiologically active peptide
|
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
|
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタｃｎｐ遺伝子及び前駆体蛋白
|
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド（カエルｃｎｐ）
|
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
|
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットＣＮＰｃＤＮＡ及び前駆体蛋白
|
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトｃｎｐ遺伝子及び前駆体蛋白
|
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Ｃｎｐ類似体ペプチド
|
|
WO1992020371A1
(en)
|
1991-05-10 |
1992-11-26 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
|
AU6360394A
(en)
|
1993-03-03 |
1994-09-26 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
|
AU4835693A
(en)
|
1993-08-13 |
1995-03-14 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
|
CA2174517C
(en)
|
1993-11-12 |
2007-01-02 |
David Lowe |
Receptor specific atrial natriuretic peptides
|
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
WO1995033769A1
(de)
|
1994-06-02 |
1995-12-14 |
Boehringer Mannheim Gmbh |
Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
|
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
|
JP2001503256A
(ja)
|
1996-10-22 |
2001-03-13 |
ジェネンテック，インコーポレーテッド |
レセプター選択的ｂｎｐ
|
|
CA2280957A1
(en)
|
1997-02-14 |
1998-08-20 |
Leslie Orgel |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
|
AU757658B2
(en)
|
1998-03-09 |
2003-02-27 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
CA2245903A1
(en)
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
|
CA2262056A1
(en)
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
|
JP2002542304A
(ja)
|
1999-04-28 |
2002-12-10 |
ベクトレイムド インコーポレイテッド |
酵素的に活性化された重合薬物接合体
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
|
JP2000327583A
(ja)
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
|
AU765753B2
(en)
|
1999-05-17 |
2003-09-25 |
Conjuchem Biotechnologies Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
|
WO2001036620A2
(en)
|
1999-11-16 |
2001-05-25 |
Genzyme Corporation |
Vectors and transgenies with regulatory elements for gene delivery to the liver
|
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
|
AU2277201A
(en)
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Novel purines
|
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
|
JP2003531179A
(ja)
|
2000-04-26 |
2003-10-21 |
クイーンズ ユニバーシティ アット キングストン |
悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
|
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
|
DE60123635T2
(de)
|
2000-08-23 |
2007-08-16 |
Enobia Pharma Inc., Montreal |
Methode und zusammensetzung zur förderung von osteogenese
|
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
|
SI1724284T1
(sl)
|
2000-12-07 |
2009-12-31 |
Lilly Co Eli |
Glp-1 fuzijski proteini
|
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
|
WO2002092020A2
(en)
|
2001-03-23 |
2002-11-21 |
The Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
|
WO2002092134A1
(en)
|
2001-05-14 |
2002-11-21 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
JP3935487B2
(ja)
|
2001-07-16 |
2007-06-20 |
フーベルト・ケスター |
捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
|
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
AU2002356392A1
(en)
|
2001-12-20 |
2003-07-09 |
Phenogene Therapeutiques Inc. |
Bone polypeptide-1
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
|
JP2005527510A
(ja)
|
2002-03-06 |
2005-09-15 |
セレジー ファーマシューティカルズ インコーポレーティッド |
癌の治療において一酸化窒素模倣体を使用するための製剤および方法
|
|
WO2003079979A2
(en)
|
2002-03-18 |
2003-10-02 |
Scios Inc. |
Method for treating congestive heart failure
|
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
|
EP1530588A2
(en)
|
2002-07-31 |
2005-05-18 |
Conjuchem, Inc. |
Long lasting natriuretic peptide derivatives
|
|
US20060110359A1
(en)
|
2002-09-06 |
2006-05-25 |
Juan Sanchez-Ramos |
Cellular delivery of natriuretic peptides
|
|
JP4610025B2
(ja)
|
2002-11-18 |
2011-01-12 |
シン．クス ファーマ、インコーポレイテッド |
ＮＴ−ｐｒｏＢＮＰ検出用ポリクローナル・モノクローナル・エライサ検定法
|
|
SG159387A1
(en)
|
2002-11-26 |
2010-03-30 |
Biocon Ltd In |
Modified natriuretic compounds, conjugates, and uses thereof
|
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
EP1572645A2
(en)
|
2002-12-03 |
2005-09-14 |
Enobia Pharma Inc. |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
|
EP1583554A2
(en)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
|
EP2196474A3
(en)
|
2003-02-14 |
2010-12-15 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
|
CA2522709A1
(en)
|
2003-04-17 |
2004-11-04 |
Ciphergen Biosystems, Inc. |
Polypeptides related to natriuretic peptides and methods of their identification and use
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
ATE490469T1
(de)
|
2003-06-17 |
2010-12-15 |
Otago Innovation Ltd |
Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
|
|
CN101208353B
(zh)
|
2003-06-20 |
2011-12-14 |
梅约医学教育与研究基金会 |
脑利尿钠肽的同种型
|
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
|
WO2005070446A1
(en)
|
2004-01-15 |
2005-08-04 |
Scios Inc. |
Method for treating cardiac remodeling following myocardial injury
|
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
BRPI0507233B8
(pt)
|
2004-03-11 |
2021-05-25 |
Genentech Inc |
processo para a produção de um polipeptídeo heterólogo em e. coli
|
|
KR20070007842A
(ko)
|
2004-03-31 |
2007-01-16 |
카즈와 나카오 |
신장증가용 조성물
|
|
ES2465141T3
(es)
|
2004-03-31 |
2014-06-05 |
Kazuwa Nakao |
Remedio o medicamento preventivo para la artritis
|
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
|
PL1759001T3
(pl)
|
2004-04-21 |
2011-09-30 |
Alexion Pharma Inc |
Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
|
|
US20090298120A1
(en)
|
2004-05-04 |
2009-12-03 |
National University Of Singapore |
Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
|
|
JP2007537263A
(ja)
*
|
2004-05-10 |
2007-12-20 |
ノバセア インコーポレイティッド |
活性ビタミンｄ化合物による動脈再狭窄の予防法
|
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
|
US7863238B2
(en)
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
|
US20070081984A1
(en)
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
|
WO2006005140A2
(en)
|
2004-07-15 |
2006-01-19 |
The University Of Queensland |
Proteinaceous compounds and uses therefor
|
|
US20090142347A1
(en)
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
|
BRPI0515819A
(pt)
|
2004-12-01 |
2008-08-05 |
Genzyme Corp |
métodos para o fornecimento direcionado de material genético ao fìgado
|
|
US7732406B2
(en)
|
2005-04-07 |
2010-06-08 |
Cardiopep Pharma Gmbh |
Use of natriuretic peptide for treating heart failure
|
|
CA2606102C
(en)
|
2005-04-26 |
2014-09-30 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
|
CA2621264A1
(en)
*
|
2005-09-06 |
2007-11-15 |
Zelos Therapeutics, Inc. |
Parathyroid hormone analogues and methods of use
|
|
WO2007035600A2
(en)
|
2005-09-16 |
2007-03-29 |
Mayo Foundation For Education And Research |
Natriuretic activities
|
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
|
DK1987178T3
(en)
|
2006-02-20 |
2015-04-20 |
Phylogica Ltd |
Process for the construction and screening of peptide structure libraries
|
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
|
EP2040758A4
(en)
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
BIORESPONSIVE POLYMERS
|
|
US8324162B2
(en)
|
2006-08-08 |
2012-12-04 |
Mayo Foundation For Medical Education And Research |
Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
|
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
|
JP2010502231A
(ja)
|
2006-09-08 |
2010-01-28 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド
|
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
|
|
PE20081140A1
(es)
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
|
US20100168443A1
(en)
|
2006-11-02 |
2010-07-01 |
University Of Virginia Patent Foundation |
Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
|
|
JP5645408B2
(ja)
*
|
2006-11-16 |
2014-12-24 |
カイ ファーマシューティカルズ インコーポレーティッド |
副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
|
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
|
EP2118665B1
(en)
|
2007-03-12 |
2012-04-18 |
Biomedica Medizinprodukte GmbH & Co KG |
Diagnosis of septic complications
|
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
|
DK2662448T3
(en)
|
2007-05-11 |
2017-03-20 |
Alexion Pharma Inc |
Bone-targeted alkaline phosphatase, kits and methods for its use
|
|
MX2009012343A
(es)
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
US20100310561A1
(en)
|
2007-06-06 |
2010-12-09 |
Boehringer Ingelheim International Gmbh |
Natriuretic fusion proteins
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
AU2008274845A1
(en)
|
2007-07-06 |
2009-01-15 |
Theratechnologies Inc. |
Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
|
|
EP2171053B1
(en)
|
2007-07-20 |
2014-04-23 |
Mayo Foundation for Medical Education and Research |
Natriuretic polypeptides
|
|
WO2009042294A2
(en)
*
|
2007-08-10 |
2009-04-02 |
Burnham Institute For Medical Research |
Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
AU2008303928A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
|
|
WO2009043468A2
(en)
|
2007-09-11 |
2009-04-09 |
Mondobiotech Laboratories Ag |
Use of corticotropin-releasing factor as a therapeutic agent
|
|
KR20100059863A
(ko)
|
2007-09-11 |
2010-06-04 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도
|
|
WO2009034134A2
(en)
|
2007-09-11 |
2009-03-19 |
Pharis Biotec Gmbh |
Use of natriuretic peptides for treating angioedema syndromes
|
|
US20100204107A1
(en)
|
2007-09-11 |
2010-08-12 |
Dorian Bevec |
Use of urodilatin as a therapeutic agent
|
|
KR20100057063A
(ko)
|
2007-09-11 |
2010-05-28 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드의 용도
|
|
WO2009036448A2
(en)
|
2007-09-15 |
2009-03-19 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-c agonists
|
|
AR069409A1
(es)
|
2007-11-21 |
2010-01-20 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
|
PT2277890E
(pt)
|
2008-05-23 |
2016-03-31 |
Daiichi Sankyo Co Ltd |
Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma
|
|
US20110152194A1
(en)
|
2008-06-06 |
2011-06-23 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
|
EP2315602A4
(en)
|
2008-06-26 |
2011-11-02 |
Acceleron Pharma Inc |
METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
|
|
DK2307447T3
(da)
|
2008-07-02 |
2016-06-20 |
Mayo Foundation |
Natriuretiske polypeptider med unikke farmakologiske profiler
|
|
EP2300501B1
(en)
|
2008-07-23 |
2014-08-20 |
Hanmi Science Co., Ltd. |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
|
US8642550B2
(en)
|
2008-10-24 |
2014-02-04 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides without hypotensive inducing capability
|
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
|
AR075029A1
(es)
|
2009-01-19 |
2011-03-02 |
Hanmi Pharm Ind Co Ltd |
Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
|
|
CA2754408A1
(en)
|
2009-03-30 |
2010-10-14 |
Boehringer Ingelheim International Gmbh |
Fusion proteins comprising canine fc portions
|
|
US20120053123A1
(en)
|
2009-05-05 |
2012-03-01 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
|
EP2432489B1
(en)
|
2009-05-20 |
2016-10-05 |
BioMarin Pharmaceutical Inc. |
Variants of c-type natriuretic peptide
|
|
US8685024B2
(en)
|
2010-04-14 |
2014-04-01 |
Arrowhead Medical Device Technologies, Llc |
Intramedullary fixation device and methods for bone fixation and stabilization
|
|
CN103153344A
(zh)
*
|
2010-04-30 |
2013-06-12 |
阿莱克森国际制药有限公司 |
用于治疗基质矿化障碍的方法、组合物、和试剂盒
|
|
JP6055779B2
(ja)
|
2010-12-27 |
2016-12-27 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
ナトリウム利尿ペプチドを含む組成物およびその使用方法
|
|
KR20140084201A
(ko)
|
2011-10-19 |
2014-07-04 |
알렉시온 파마 홀딩 |
알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
|
|
MX355063B
(es)
|
2011-11-10 |
2018-04-04 |
Kai Pharmaceuticals Inc |
Calcimiméticos y métodos para su uso.
|
|
US10052366B2
(en)
*
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
BR112015001712A2
(pt)
|
2012-07-25 |
2017-07-04 |
Psioxus Therapeutics Ltd |
uso de s-pindolol para o tratamento da caquexia e sarcopenia
|
|
US20160097100A1
(en)
|
2013-05-17 |
2016-04-07 |
Jeffrey Trent |
Genetic test to predict patient response to bone morphogenetic protein in arthrodesis
|
|
DK3461891T3
(da)
|
2014-01-24 |
2020-08-10 |
Am-Pharma Bv |
Nedstrømsbehandling af en alkalisk phosphatase
|
|
WO2015112017A1
(en)
|
2014-01-24 |
2015-07-30 |
Am-Pharma B.V. |
Chimeric alkaline phosphatase-like proteins
|
|
DK3845245T3
(da)
|
2014-06-09 |
2025-09-15 |
Ultragenyx Pharmaceutical Inc |
Effektiv og virkningsfuld kontrol af serumphosphat til optimal knogledannelse
|
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
|
JP6948942B2
(ja)
|
2014-10-15 |
2021-10-13 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
|
|
JP6787894B2
(ja)
|
2014-12-05 |
2020-11-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
組換えアルカリホスファターゼを用いた発作の処置
|
|
CA2973883A1
(en)
|
2015-01-28 |
2016-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
|
KR101867134B1
(ko)
|
2015-03-23 |
2018-06-12 |
한양대학교 산학협력단 |
포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
|
|
JP6993961B2
(ja)
|
2015-08-17 |
2022-01-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
アルカリホスファターゼの製造
|
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
|
EP3368062A4
(en)
|
2015-10-30 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
|
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
|
KR20180125979A
(ko)
|
2016-04-01 |
2018-11-26 |
알렉시온 파마슈티칼스, 인코포레이티드 |
알칼리성 포스파타아제로 근육 약화의 치료
|
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
|
US20200306350A1
(en)
|
2016-06-27 |
2020-10-01 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children and adolescents
|
|
JP7018933B2
(ja)
|
2016-08-18 |
2022-02-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
気管気管支軟化症の治療方法
|
|
EP3526328A4
(en)
|
2016-10-17 |
2020-05-27 |
Apellis Pharmaceuticals, Inc. |
COMBINATION THERAPY FOR C3 INHIBITION
|
|
EP3592372A4
(en)
|
2017-03-09 |
2021-01-13 |
Alexion Pharmaceuticals, Inc. |
GLYCOPROTEIN MANUFACTURING PROCESS
|
|
WO2019190752A1
(en)
|
2018-03-30 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of glycoproteins
|
|
CA3158320A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|